TABLE 3.

Patient Characteristics

	Palbociclib	Ribociclib	Abemaciclib
Number of patients (100% female)	27	26	23
Number of patients treated with CDK4/6i plus letrozole	14	20	18
Mean age (range)	63 (36–80)	58 (34–81)	59 (35–81)
CDK4/6i setting	Adjuvant: 0 First line: 19 Second line: 8	Adjuvant: 1 First line: 23 Second line: 2	Adjuvant: 6 First line: 15 Second line: 1
Hormonal status	Premenopausal: 6 Menopausal: 21	Premenopausal: 7 Menopausal: 19	Premenopausal: 5 Menopausal: 18
Dose (mg/d) (number of patients)*	75 (7); 100 (6); 125 (14)	300 (1); 400 (5*); 600 (21)	100 (2); 200 (2); 300 (19)
Time (h) after last administration ±SD (range)	24 ± 1 (21.5–26.5)	23.5 ± 2.5 (12.5–26.5)	13 ± 4.5 (4.0–24.5)

^*The dose of ribociclib was reduced from 600 to 400 mg/mL for 1 patient.